Sweden: Subscription period for Karo Pharma’s rights issue begins

Karo Pharma, the Sweden-based healthcare business that owns and commercialises branded, original over-the-counter products and prescription medicines, is opening subscription on its Skr2.5bn (US$260m) rights issue.   Proceeds from the rights issue is planned to repay the bridge loan, provided by SEB, Swedbank, DNB and Alecta, that financed its acquisition of Belgium-based Sylphar in November 2021…

You must be a HMI Subscriber to view this content.

Subscribe Now »